PALISADE BIO, INC.·4

Jul 10, 6:14 PM ET

Baltera Robert Jr. 4

Research Summary

AI-generated summary

Updated

Palisade Bio (PALI) Director Robert Baltera Jr. Buys 45,000 Shares

What Happened
Robert Baltera Jr., a director of Palisade Bio, purchased a total of 45,000 shares of PALI stock in two open-market transactions: 20,000 shares on 2026-07-08 at a weighted average price of $1.99 (≈ $39,798) and 25,000 shares on 2026-07-09 at a weighted average price of $1.96 (≈ $48,900). These were purchases (SEC code P), increasing his stake in the company. Total consideration for the two transactions was about $88,698.

Key Details

  • Transaction dates and reported prices:
    • 2026-07-08: 20,000 shares, weighted avg $1.99 (total ≈ $39,798). Footnote F1: prices in the trades ranged from $1.98 to $2.00.
    • 2026-07-09: 25,000 shares, weighted avg $1.96 (total ≈ $48,900). Footnote F2: prices in the trades ranged from $1.9298 to $1.98.
  • Aggregate purchased: 45,000 shares for ≈ $88,698.
  • Post-transaction holdings: not disclosed in the information provided / not included in the supplied excerpt.
  • Filing timeliness: Form 4 was filed on 2026-07-10 covering the July 8–9 transactions — appears timely (within the SEC’s two-business-day reporting window).
  • Notes: Both entries use footnotes indicating the reported column 4 prices are weighted averages across multiple executions; the filer offers to provide per-trade breakdowns on request.

Context
These were straightforward open-market purchases by a company director. Insider purchases are often watched by investors as one of several signals about management’s view of valuation, but they do not guarantee future performance. The weighted-average pricing and footnotes mean the trades occurred in multiple executions at slightly different prices; full per-trade pricing is available from the filer upon request.